Guangrong Zheng

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 51

Top Topics

Histone Deacetylase

Finite Element Analysis

Top Venues

Journal of medicinal chemistry

The Journal of experimental medicine

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Digant Nayak, Dong-Wen Lv, Yaxia Yuan, Peiyi Zhang, Wanyi Hu, Anindita Nayak, Eliza A Ruben, Zongyang Lv, Patrick Sung, Robert Hromas, Guangrong Zheng, Daohong Zhou, Shaun K Olsen
Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL. Nature communications 15 (1) (2024)
Digant Nayak, Dong-Wen Lv, Yaxia Yuan, Peiyi Zhang, Wanyi Hu, Anindita Nayak, Eliza A Ruben, Zongyang Lv, Patrick Sung, Robert Hromas, Guangrong Zheng, Daohong Zhou, Shaun K Olsen
Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL. Nature communications 15 (1) (2024)
Yufeng Xiao, Yaxia Yuan, Yi Liu, Zongtao Lin, Guangrong Zheng, Daohong Zhou, Dongwen Lv
Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution. Journal of medicinal chemistry 67 (14) (2024)
Yufeng Xiao, Yaxia Yuan, Yi Liu, Zongtao Lin, Guangrong Zheng, Daohong Zhou, Dongwen Lv
Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution. Journal of medicinal chemistry 67 (14) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Sajid Khan, Lin Cao, Janet Wiegand, Peiyi Zhang, Maria Zajac-Kaye, Frederic J Kaye, Guangrong Zheng, Daohong Zhou
PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. Cells 13 (6) (2024)
Sajid Khan, Lin Cao, Janet Wiegand, Peiyi Zhang, Maria Zajac-Kaye, Frederic J Kaye, Guangrong Zheng, Daohong Zhou
PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. Cells 13 (6) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Yufeng Xiao, Yaxia Yuan, Yi Liu, Zongtao Lin, Guangrong Zheng, Daohong Zhou, Dongwen Lv
Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution. Journal of medicinal chemistry (2024)
Yufeng Xiao, Yaxia Yuan, Yi Liu, Zongtao Lin, Guangrong Zheng, Daohong Zhou, Dongwen Lv
Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution. Journal of medicinal chemistry 67 (14) (2024)
Digant Nayak, Dong-Wen Lv, Yaxia Yuan, Peiyi Zhang, Wanyi Hu, Anindita Nayak, Eliza A Ruben, Zongyang Lv, Patrick Sung, Robert Hromas, Guangrong Zheng, Daohong Zhou, Shaun K Olsen
Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL. Nature communications 15 (1) (2024)
Sajid Khan, Lin Cao, Janet Wiegand, Peiyi Zhang, Maria Zajac-Kaye, Frederic J Kaye, Guangrong Zheng, Daohong Zhou
PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. Cells 13 (6) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Digant Nayak, Dong-Wen Lv, Yaxia Yuan, Peiyi Zhang, Wanyi Hu, Anindita Nayak, Eliza A Ruben, Zongyang Lv, Patrick Sung, Robert Hromas, Guangrong Zheng, Daohong Zhou, Shaun K Olsen
Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL. Nature communications 15 (1) (2024)
Michael Y He, Kit I Tong, Ting Liu, Ryder Whittaker Hawkins, Victoria Shelton, Yong Zeng, Mehran Bakhtiari, Yufeng Xiao, Guangrong Zheng, Ali Sakhdari, Lin Yang, Wenxi Xu, David G Brooks, Rob C Laister, Housheng Hansen He, Robert Kridel
GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. Leukemia (2024)
Sajid Khan, Lin Cao, Janet Wiegand, Peiyi Zhang, Maria Zajac-Kaye, Frederic J Kaye, Guangrong Zheng, Daohong Zhou
PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. Cells 13 (6) (2024)
Yufeng Xiao, Yaxia Yuan, Yi Liu, Zongtao Lin, Guangrong Zheng, Daohong Zhou, Dongwen Lv
Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution. Journal of medicinal chemistry 67 (14) (2024)
Yufeng Xiao, Nikee Awasthee, Yi Liu, Chengcheng Meng, Michael Y He, Seth Hale, Rashmi Karki, Zongtao Lin, Megan Mosterio, Benjamin A Garcia, Robert Kridel, Daiqing Liao, Guangrong Zheng
Discovery of a Highly Potent and Selective HDAC8 Degrader: Advancing the Functional Understanding and Therapeutic Potential of HDAC8. Journal of medicinal chemistry (2024)
Yufeng Xiao, Nikee Awasthee, Yi Liu, Chengcheng Meng, Michael Y He, Seth Hale, Rashmi Karki, Zongtao Lin, Megan Mosterio, Benjamin A Garcia, Robert Kridel, Daiqing Liao, Guangrong Zheng
Discovery of a Highly Potent and Selective HDAC8 Degrader: Advancing the Functional Understanding and Therapeutic Potential of HDAC8. Journal of medicinal chemistry (2024)
Michael Y He, Kit I Tong, Ting Liu, Ryder Whittaker Hawkins, Victoria Shelton, Yong Zeng, Mehran Bakhtiari, Yufeng Xiao, Guangrong Zheng, Ali Sakhdari, Lin Yang, Wenxi Xu, David G Brooks, Rob C Laister, Housheng Hansen He, Robert Kridel
GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. Leukemia (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Sajid Khan, Lin Cao, Janet Wiegand, Peiyi Zhang, Maria Zajac-Kaye, Frederic J Kaye, Guangrong Zheng, Daohong Zhou
PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. Cells 13 (6) (2024)
Digant Nayak, Dong-Wen Lv, Yaxia Yuan, Peiyi Zhang, Wanyi Hu, Anindita Nayak, Eliza A Ruben, Zongyang Lv, Patrick Sung, Robert Hromas, Guangrong Zheng, Daohong Zhou, Shaun K Olsen
Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL. Nature communications 15 (1) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Yufeng Xiao, Nikee Awasthee, Yi Liu, Chengcheng Meng, Michael Y He, Seth Hale, Rashmi Karki, Zongtao Lin, Megan Mosterio, Benjamin A Garcia, Robert Kridel, Daiqing Liao, Guangrong Zheng
Discovery of a Highly Potent and Selective HDAC8 Degrader: Advancing the Functional Understanding and Therapeutic Potential of HDAC8. Journal of medicinal chemistry 67 (15) (2024)
Sajid Khan, Lin Cao, Janet Wiegand, Peiyi Zhang, Maria Zajac-Kaye, Frederic J Kaye, Guangrong Zheng, Daohong Zhou
PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. Cells 13 (6) (2024)
Yufeng Xiao, Nikee Awasthee, Yi Liu, Chengcheng Meng, Michael Y He, Seth Hale, Rashmi Karki, Zongtao Lin, Megan Mosterio, Benjamin A Garcia, Robert Kridel, Daiqing Liao, Guangrong Zheng
Discovery of a Highly Potent and Selective HDAC8 Degrader: Advancing the Functional Understanding and Therapeutic Potential of HDAC8. Journal of medicinal chemistry 67 (15) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Miao Huang, Heyang Wang, Cole Mackey, Michael C Chung, Juan Guan, Guangrong Zheng, Arkaprava Roy, Mingyi Xie, Christopher Vulpe, Xin Tang
YAP at the Crossroads of Biomechanics and Drug Resistance in Human Cancer. International journal of molecular sciences 24 (15) (2023)
Sajid Khan, Patrick Kellish, Nick Connis, Dinesh Thummuri, Janet Wiegand, Peiyi Zhang, Xuan Zhang, Vivekananda Budamagunta, Nan Hua, Yang Yang, Umasankar De, Lingtao Jin, Weizhou Zhang, Guangrong Zheng, Robert Hromas, Christine Hann, Maria Zajac-Kaye, Frederic J Kaye, Daohong Zhou
Co-targeting BCL-X L and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice. Cell death discovery 9 (1) (2023)
Sajid Khan, Patrick Kellish, Nick Connis, Dinesh Thummuri, Janet Wiegand, Peiyi Zhang, Xuan Zhang, Vivekananda Budamagunta, Nan Hua, Yang Yang, Umasankar De, Lingtao Jin, Weizhou Zhang, Guangrong Zheng, Robert Hromas, Christine Hann, Maria Zajac-Kaye, Frederic J Kaye, Daohong Zhou
Co-targeting BCL-X L and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice. Cell death discovery 9 (1) (2023)
Sajid Khan, Patrick Kellish, Nick Connis, Dinesh Thummuri, Janet Wiegand, Peiyi Zhang, Xuan Zhang, Vivekananda Budamagunta, Nan Hua, Yang Yang, Umasankar De, Lingtao Jin, Weizhou Zhang, Guangrong Zheng, Robert Hromas, Christine Hann, Maria Zajac-Kaye, Frederic J Kaye, Daohong Zhou
Co-targeting BCL-X L and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice. Cell death discovery 9 (1) (2023)
Sajid Khan, Patrick Kellish, Nick Connis, Dinesh Thummuri, Janet Wiegand, Peiyi Zhang, Xuan Zhang, Vivekananda Budamagunta, Nan Hua, Yang Yang, Umasankar De, Lingtao Jin, Weizhou Zhang, Guangrong Zheng, Robert Hromas, Christine Hann, Maria Zajac-Kaye, Frederic J Kaye, Daohong Zhou
Co-targeting BCL-X L and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice. Cell death discovery 9 (1) (2023)
Sajid Khan, Patrick Kellish, Nick Connis, Dinesh Thummuri, Janet Wiegand, Peiyi Zhang, Xuan Zhang, Vivekananda Budamagunta, Nan Hua, Yang Yang, Umasankar De, Lingtao Jin, Weizhou Zhang, Guangrong Zheng, Robert Hromas, Christine Hann, Maria Zajac-Kaye, Frederic J Kaye, Daohong Zhou
Co-targeting BCL-X L and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice. Cell death discovery 9 (1) (2023)
Yunhan Jiang, Lina Song, Yizhu Lin, Pawel Nowialis, Qiongmei Gao, Tao Li, Bin Li, Xiaobo Mao, Qianqian Song, Chengguo Xing, Guangrong Zheng, Shuang Huang, Lingtao Jin
ROS-mediated SRMS activation confers platinum resistance in ovarian cancer. Oncogene (2023)
Pataje G S Prasanna, Deborah E Citrin, Jeffrey Hildesheim, Mansoor M Ahmed, Sundar Venkatachalam, Gabriela Riscuta, Dan Xi, Guangrong Zheng, Jan van Deursen, Jorg J Goronzy, Stephen J Kron, Mitchell S Anscher, Norman E Sharpless, Pierre-Yves Desprez, Stephen L Brown, Laura J Niedernhofer, Ana O'Loghlen, Alexandros G Georgakilas, François Paris, David Gius, David A Gewirtz, Clemens A Schmitt, Mohamed E Abazeed, James L Kirkland, Ann Richmond, Paul B Romesser, Scott W Lowe, Jesús Gil, Marc S Mendonca, Sandeep Burma, Daohong Zhou, C Norman Coleman
Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy. Journal of the National Cancer Institute 113 (10) (2022)
Yanjun Li, Daohong Zhou, Guangrong Zheng, Xiaolin Li, Dapeng Wu, Yaxia Yuan
DyScore: A Boosting Scoring Method with Dynamic Properties for Identifying True Binders and Nonbinders in Structure-Based Drug Discovery. Journal of chemical information and modeling 62 (22) (2022)
Pratik Pal, Dinesh Thummuri, Dongwen Lv, Xingui Liu, Peiyi Zhang, Wanyi Hu, Saikat K Poddar, Nan Hua, Sajid Khan, Yaxia Yuan, Xuan Zhang, Daohong Zhou, Guangrong Zheng
Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition. Journal of medicinal chemistry 64 (19) (2021)
Dong-Wen Lv, Pratik Pal, Xingui Liu, Yannan Jia, Dinesh Thummuri, Peiyi Zhang, Wanyi Hu, Jing Pei, Qi Zhang, Shuo Zhou, Sajid Khan, Xuan Zhang, Nan Hua, Qingping Yang, Sebastian Arango, Weizhou Zhang, Digant Nayak, Shaun K Olsen, Susan T Weintraub, Robert Hromas, Marina Y Konopleva, Yaxia Yuan, Guangrong Zheng, Daohong Zhou
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nature communications 12 (1) (2021)
Yufeng Xiao, Jia Wang, Lisa Y Zhao, Xinyi Chen, Guangrong Zheng, Xuan Zhang, Daiqing Liao
Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs. Chemical communications (Cambridge, England) 56 (68) (2021)
Dinesh Thummuri, Sajid Khan, Patrick W Underwood, Peiyi Zhang, Janet Wiegand, Xuan Zhang, Vivekananda Budamagunta, Amin Sobh, Abderrahmane Tagmount, Alexander Loguinov, Andrea N Riner, Ashwin S Akki, Elizabeth Williamson, Robert Hromas, Christopher D Vulpe, Guangrong Zheng, Jose G Trevino, Daohong Zhou
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216. Molecular cancer therapeutics (2021)
Ryan Kolb, Umasankar De, Sajid Khan, Yuewan Luo, Myung-Chul Kim, Haijun Yu, Chaoyan Wu, Jiao Mo, Xin Zhang, Peiyi Zhang, Xuan Zhang, Nicholas Borcherding, Daniel Koppel, Yang-Xin Fu, Song Guo Zheng, Dorina Avram, Guangrong Zheng, Daohong Zhou, Weizhou Zhang
Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nature communications 12 (1) (2021)
Satheesh Gujarathi, Maroof Khan Zafar, Xingui Liu, Robert L Eoff, Guangrong Zheng
A Facile Semisynthesis and Evaluation of Garcinoic Acid and Its Analogs for the Inhibition of Human DNA Polymerase β. Molecules (Basel, Switzerland) 25 (24) (2020)
Xuan Zhang, Xingui Liu, Daohong Zhou, Guangrong Zheng
Targeting anti-apoptotic BCL-2 family proteins for cancer treatment. Future medicinal chemistry 12 (7) (2020)
Yong-Han He, Xuan Zhang, Jianhui Chang, Ha-Neui Kim, Peiyi Zhang, Yingying Wang, Sajid Khan, Xingui Liu, Xin Zhang, Dong-Wen Lv, Lin Song, Wen Li, Dinesh Thummuri, Yaxia Yuan, Janet S Wiegand, Yuma T Ortiz, Vivekananda Budamagunta, Jennifer H Elisseeff, Judith Campisi, Maria Almeida, Guangrong Zheng, Daohong Zhou
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nature communications 11 (1) (2020)
Peiyi Zhang, Xuan Zhang, Xingui Liu, Sajid Khan, Daohong Zhou, Guangrong Zheng
PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors. Exploration of targeted anti-tumor therapy 1 (2020)
Xingui Liu, Saikat Poddar, Lin Song, Howard Hendrickson, Xuan Zhang, Yaxia Yuan, Daohong Zhou, Guangrong Zheng
Synthesis and Liver Microsomal Metabolic Stability Studies of a Fluorine-Substituted δ-Tocotrienol Derivative. ChemMedChem 15 (6) (2020)
Sajid Khan, Xuan Zhang, Dong-Wen Lv, Qi Zhang, Yonghan He, Peiyi Zhang, Xingui Liu, Dinesh Thummuri, Yaxia Yuan, Janet S Wiegand, Jing Pei, Weizhou Zhang, Abhisheak Sharma, Christopher R McCurdy, Vinitha M Kuruvilla, Natalia Baran, Adolfo A Ferrando, Yong-Mi Kim, Anna Rogojina, Peter J Houghton, Guangcun Huang, Robert Hromas, Marina Konopleva, Guangrong Zheng, Daohong Zhou
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nature medicine 25 (12) (2019)